Table 2.

Change in Fatty Acid Composition (%) After Two-Weeks of Atorvastatin or No-Treatment.

Table 2A Fatty acid	No Treatment (n = 10) Baseline	Follow-up	p-value
12:0	0.24 ± 0.24	0.21 ± 0.23	0.11
14:0	0.93 ± 0.34	0.70 ± 0.24	0.02
14:1	0.17 ± 0.11	0.14 ± 0.13	0.11
16:0	21.86 ± 1.97	21.33 ± 1.28	0.49
16:1	1.63 ± 0.36	1.39 ± 0.27	0.06
18:0	7.64 ± 1.34	7.65 ± 1.12	0.99
18:1n-9	18.11±2.17	18.05 ± 2.11	0.9
18:1n-7	1.33 ± 0.33	1.35 ± 0.25	0.85
18:2n-6 (LA)	33.51 ± 4.52	35.15 ± 5.08	0.26
18:3n-6	0.46 ± 0.18	0.4 ± 0.16	0.42
18:3n-3	0.61 ± 0.2	0.56 ± 0.24	0.46
20:0	0.2 ± 0.05	0.18 ± 0.04	0.41
20:1	0.12 ± 0.03	0.11 ± 0.03	0.35
20:2n-6	0.14 ± 0.04	0.18 ± 0.11	0.19
20:3n-6	1.36 ± 0.49	1.33 ± 0.48	0.79
20:4n-6 (AA)	7.88 ± 1.07	7.77±2.17	0.85
20:5n-3	1.27 ± 2.03	0.46 ± 0.17	0.24
22:4n-6	0.17 ± 0.05	0.16 ± 0.05	0.57
24:0	0.16 ± 0.06	0.14 ± 0.05	0.32
22:5n-3	0.48 ± 0.19	0.46±0.17	0.62
22:6n-3	1.6 ± 1.07	1.6 ± 1.11	0.99
Table 2B Fatty acid	Statin (n = 20) Baseline	Follow-up	p-value
12:0	0.27 ± 0.22	0.37 ± 0.3	0.03
14:0	0.88 ± 0.43	0.84 ± 0.5	0.69
14:1	0.17 ± 0.14	0.21 ± 0.18	0.06
16:0	22.29 ± 2.38	21.83 ± 2.27	0.35
16:1	1.64 ± 0.84	1.71 ± 1.00	0.59
18:0	8.07 ± 1.16	8.31 ± 1.32	0.11
18:1n-9	18.50 ± 2.48	20.56 ± 5.08	0.06
18:1n-7	1.39 ± 0.36	1.63 ± 0.35	0.001
18:2n-6 (LA)	33.31 ± 4.84	29.76 ± 4.15	0.002
18:3n-6	0.45 ± 0.24	0.45 ± 0.16	0.95
18:3n-3	0.62 ± 0.19	0.63 ± 0.37	0.84
20:0	0.18± 0.06	0.19 ± 0.09	0.35
20:1	0.14 ± 0.04	0.18 ± 0.09	0.03
20:2n-6	0.18 ± 0.05	0.18 ± 0.04	0.59
20:3n-6	1.29 ± 0.25	1.26 ± 0.25	0.54
20:4n-6 (AA)	7.73 ± 1.38	8.99 ± 2.10	0.007
20:5n-3	0.60 ± 0.35	0.62 ± 0.28	0.88
22:4n-6	0.18 ± 0.04	0.19 ± 0.04	0.2
24:0	0.19 ± 0.13	0.16 ± 0.09	0.13
22:5n-3	0.43 ± 0.08	0.42 ± 0.09	0.84
22:6n-3	1.48 ± 0.53	1.49 ± 0.58	0.84

Data are mean ± SD with fatty acid composition as a percent of the whole. AA; arachidonic acid. LA; Linoleic acid.